WO2026076332A1 - Procédés faisant intervenir l'identification multimodale des variants tumoraux et le suivi des molécules tumorales - Google Patents

Procédés faisant intervenir l'identification multimodale des variants tumoraux et le suivi des molécules tumorales

Info

Publication number
WO2026076332A1
WO2026076332A1 PCT/US2025/049392 US2025049392W WO2026076332A1 WO 2026076332 A1 WO2026076332 A1 WO 2026076332A1 US 2025049392 W US2025049392 W US 2025049392W WO 2026076332 A1 WO2026076332 A1 WO 2026076332A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
sample
sequencing
methylation
deaminase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/049392
Other languages
English (en)
Inventor
Andrew Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guardant Health Inc
Original Assignee
Guardant Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guardant Health Inc filed Critical Guardant Health Inc
Publication of WO2026076332A1 publication Critical patent/WO2026076332A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés liés à l'analyse de l'ADN dans un échantillon prélevé sur un sujet, consistant à mesurer dans l'échantillon ou un sous-échantillon de celui-ci un niveau de méthylation d'une ou de plusieurs variantes de régions à méthylation différentielle (DMR) indépendamment d'une ou de plusieurs DMR correspondantes, la ou les variantes de DMR comportant une mutation somatique que la ou les DMR correspondantes ne comportent pas.
PCT/US2025/049392 2024-10-03 2025-10-03 Procédés faisant intervenir l'identification multimodale des variants tumoraux et le suivi des molécules tumorales Pending WO2026076332A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463703112P 2024-10-03 2024-10-03
US63/703,112 2024-10-03
US202563752333P 2025-01-31 2025-01-31
US63/752,333 2025-01-31

Publications (1)

Publication Number Publication Date
WO2026076332A1 true WO2026076332A1 (fr) 2026-04-09

Family

ID=97677001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/049392 Pending WO2026076332A1 (fr) 2024-10-03 2025-10-03 Procédés faisant intervenir l'identification multimodale des variants tumoraux et le suivi des molécules tumorales

Country Status (1)

Country Link
WO (1) WO2026076332A1 (fr)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053519A1 (en) 1990-12-06 2001-12-20 Fodor Stephen P.A. Oligonucleotides
US20030152490A1 (en) 1994-02-10 2003-08-14 Mark Trulson Method and apparatus for imaging a sample on a device
US7537898B2 (en) 2001-11-28 2009-05-26 Applied Biosystems, Llc Compositions and methods of selective nucleic acid isolation
US20110160078A1 (en) 2009-12-15 2011-06-30 Affymetrix, Inc. Digital Counting of Individual Molecules by Stochastic Attachment of Diverse Labels
US20150299767A1 (en) 2012-06-18 2015-10-22 Nugen Technologies, Inc. Compositions and methods for negative selection of non-desired nucleic acid sequences
US9598731B2 (en) 2012-09-04 2017-03-21 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20170211143A1 (en) 2014-07-25 2017-07-27 University Of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
US9738894B2 (en) 2003-03-21 2017-08-22 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
WO2018009723A1 (fr) 2016-07-06 2018-01-11 Guardant Health, Inc. Procédés de profilage d'un fragmentome d'acides nucléiques sans cellule
US9902992B2 (en) 2012-09-04 2018-02-27 Guardant Helath, Inc. Systems and methods to detect rare mutations and copy number variation
WO2018119452A2 (fr) 2016-12-22 2018-06-28 Guardant Health, Inc. Procédés et systèmes pour analyser des molécules d'acide nucléique
US10260088B2 (en) 2015-10-30 2019-04-16 New England Biolabs, Inc. Compositions and methods for analyzing modified nucleotides
WO2020160414A1 (fr) 2019-01-31 2020-08-06 Guardant Health, Inc. Compositions et méthodes pour isoler de l'adn acellulaire
US10961525B2 (en) 2017-07-05 2021-03-30 The Trustees Of The University Of Pennsylvania Hyperactive AID/APOBEC and hmC dominant TET enzymes
WO2023197004A1 (fr) * 2022-04-07 2023-10-12 Guardant Health, Inc. Détection de la présence d'une tumeur fondée sur l'état de méthylation des molécules d'acide nucléique acellulaire

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US20010053519A1 (en) 1990-12-06 2001-12-20 Fodor Stephen P.A. Oligonucleotides
US20030152490A1 (en) 1994-02-10 2003-08-14 Mark Trulson Method and apparatus for imaging a sample on a device
US7537898B2 (en) 2001-11-28 2009-05-26 Applied Biosystems, Llc Compositions and methods of selective nucleic acid isolation
US9738894B2 (en) 2003-03-21 2017-08-22 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
US20110160078A1 (en) 2009-12-15 2011-06-30 Affymetrix, Inc. Digital Counting of Individual Molecules by Stochastic Attachment of Diverse Labels
US20150299767A1 (en) 2012-06-18 2015-10-22 Nugen Technologies, Inc. Compositions and methods for negative selection of non-desired nucleic acid sequences
US9598731B2 (en) 2012-09-04 2017-03-21 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US9902992B2 (en) 2012-09-04 2018-02-27 Guardant Helath, Inc. Systems and methods to detect rare mutations and copy number variation
US20170211143A1 (en) 2014-07-25 2017-07-27 University Of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
US10260088B2 (en) 2015-10-30 2019-04-16 New England Biolabs, Inc. Compositions and methods for analyzing modified nucleotides
WO2018009723A1 (fr) 2016-07-06 2018-01-11 Guardant Health, Inc. Procédés de profilage d'un fragmentome d'acides nucléiques sans cellule
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
WO2018119452A2 (fr) 2016-12-22 2018-06-28 Guardant Health, Inc. Procédés et systèmes pour analyser des molécules d'acide nucléique
US10961525B2 (en) 2017-07-05 2021-03-30 The Trustees Of The University Of Pennsylvania Hyperactive AID/APOBEC and hmC dominant TET enzymes
WO2020160414A1 (fr) 2019-01-31 2020-08-06 Guardant Health, Inc. Compositions et méthodes pour isoler de l'adn acellulaire
WO2023197004A1 (fr) * 2022-04-07 2023-10-12 Guardant Health, Inc. Détection de la présence d'une tumeur fondée sur l'état de méthylation des molécules d'acide nucléique acellulaire

Non-Patent Citations (76)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. tig00000754-10-8122160_273
"MGnify", Database accession no. MGYP001011623624
"UniProt", Database accession no. tr|AOA6B3W113|/A0A6B3W113_9BACI
AMIT TIROSH ET AL: "Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors", CANCER, AMERICAN CANCER SOCIETY , PHILADELPHIA , PA, US, vol. 125, no. 8, 8 January 2019 (2019-01-08), pages 1247 - 1257, XP071177819, ISSN: 0008-543X, DOI: 10.1002/CNCR.31930 *
BASHTRYKOV PI ET AL.: "The UHRF 1 protein stimulates the activity and specificity of the maintenance DNA methyltransferase DNMT1 by an allosteric mechanism", J BIOL CHEM., 2014
BELINKSY, ANNU. REV. PHYSIOL., vol. 77, 2015, pages 453 - 74
BLANCO ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 8935 - 8940
BOCK ET AL., NAT BIOTECH, vol. 28, 2010, pages 1106 - 1114
CORONEL: "Database Systems: Design, Implementation, & Management", 2014
CUDDAPAH ET AL., GENOME RES., vol. 19, 2009, pages 24 - 32
ELMASRI: "Fundamentals of Database Systems", 2010
FIILLGRABE ET AL., BIORXIV, 2022
FLAVIALIMACOSTA FALDONI ET AL: "DNA methylation profile of inflammatory breast cancer and its impact on prognosis and outcome", CLINICAL EPIGENETICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 16, no. 1, 6 July 2024 (2024-07-06), pages 1 - 15, XP021340070, DOI: 10.1186/S13148-024-01695-X *
FREIER ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 4429 - 4443
FURONAKA ET AL., PATHOLOGY INTERNATIONAL, vol. 55, 2005, pages 303 - 309
GAJULA ET AL., NUCLEIC ACIDS RES., vol. 42, no. 15, September 2014 (2014-09-01), pages 9964 - 75
GALE ET AL., PLOS ONE, vol. 13, 2018, pages 0194630
GANSAUGE ET AL., NATURE PROTOCOLS, vol. 8, 2013, pages 737 - 748
GOMES ET AL., REV. PORT. PNEUMOL., vol. 20, 2014, pages 20 - 30
GOUILKENIRY, ESSAYS IN BIOCHEMISTRY, vol. 63, 2019, pages 639 - 648
GUO ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 7917 - 24
GUO ET AL., NAT. COMMUN., vol. 9, 2018, pages 1520
HELLER ET AL., ONCOGENE, vol. 25, 2006, pages 959 - 968
HENNION ET AL., GENOME BIOLOGY, vol. 21, no. 125, 2020
HOPKINS-DONALDSON ET AL., CELL DEATH DIFFER., vol. 10, 2003, pages 356 - 64
HULBERT ET AL., CLIN. CANCER RES., vol. 23, 2017, pages 1998 - 2005
IURLARO ET AL., GENOME BIOL., vol. 14, 2013, pages R119
JANG ET AL., GENES, vol. 8, no. 6, June 2017 (2017-06-01), pages 148
KANG ET AL., GENOME BIOL., vol. 18, 2017, pages 53
KANG ET AL.: "Genome Biology", vol. 18, 2017, article "Cancer Genome Atlas.", pages: 53
KATAINEN ET AL., NATURE GENETICS, 8 June 2015 (2015-06-08)
KIKUCHI ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 2954 - 61
KIM ET AL., ONCOGENE, vol. 20, 2001, pages 1765 - 70
KINDE ET AL., PROC NAT'L ACAD SCI USA, vol. 108, 2011, pages 9530 - 9535
KO ET AL., NATURE, vol. 468, 2010, pages 839 - 843
KOU ET AL., PLOS ONE, vol. 11, 2016, pages 0146638
KUROSE: "Computer Networking: A Top-Down Approach", 2016
KUTYAVIN, BIOCHEMISTRY, vol. 47, no. 51, 2008, pages 13666 - 1367
LAM ET AL., BIOCHIM BIOPHYS ACTA, vol. 1866, 2016, pages 106 - 20
LICCHESI ET AL., CARCINOGENESIS, vol. 29, 2008, pages 895 - 904
LIM ET AL., COMMUNICATIONS BIOLOGY., vol. 8, 2025, pages 1098
LISSA ET AL., TRANSL LUNG CANCER RES, vol. 5, no. 5, 2016, pages 492 - 504
LIU ET AL., NAT CHEM BIOL, vol. 13, 2017, pages 181 - 187
LIZARD ET AL., NAT. GENETICS, vol. 19, 1998, pages 225 - 232
LOU ET AL., PROC. NATL. ACAD. SCI., vol. 110, no. 49, 2013, pages 19872 - 19877
MARTIN ET AL., NAT. STRUCT. MOL. BIOL., vol. 18, 2011, pages 708 - 14
MULLER ET AL., NATURE METHODS, vol. 16, 2019, pages 429 - 436
NOTOMI ET AL., NUC. ACIDS RES., vol. 28, 2000, pages 63
NUCLEIC ACIDS RES, 2018
PALMISANO ET AL., CANCER RES., vol. 63, 2003, pages 4620 - 4625
PARDOLL, NATURE REVIEWS CANCER, vol. 12, 2012, pages 252 - 264
PETERSON: "Cloud Computing Architected: Solution Design Handbook", 2011, RECURSIVE PRESS
RHEE ET AL., CELL, vol. 147, 2011, pages 1408 - 19
ROBERTSON ET AL., NUCLEIC ACIDS RES., vol. 39, 2011, pages 8740 - 8751
SCHNEIDER ET AL., BMC CANCER, vol. 11, 2011, pages 102
SCHUTSKY ET AL., NATURE BIOTECHNOLOGY, vol. 36, 2018, pages 1083 - 1090
SCHUTSKY ET AL., NUCLEIC ACIDS RES., vol. 45, no. 13, 27 July 2017 (2017-07-27), pages 7655 - 7665
SCOTT, C.A.DURYEA, J.D.MACKAY, H. ET AL.: "Identification of cell type-specific methylation signals in bulk whole genome bisulfite sequencing data", GENOME BIOL, vol. 21, 2020, pages 156
SHI ET AL., BMC GENOMICS, vol. 18, 2017, pages 901
SKVORTSOVA ET AL., BR. J. CANCER., vol. 94, no. 10, 2006, pages 1492 - 1495
SNYDER ET AL., CELL, vol. 164, 2016, pages 57 - 68
SONG ET AL., NAT BIOTECH, vol. 29, 2011, pages 68 - 72
SONG ET AL., NAT. BIOTECH., vol. 29, 2010, pages 68 - 72
TOYOOKA ET AL., CANCER RES., vol. 61, 2001, pages 4556 - 4560
TROLL ET AL., BMC GENOMICS, vol. 20, 2019, pages 1023, Retrieved from the Internet <URL:https://doi.org/10.1186/s12864-019-6355-0>
TUCKER: "Programming Languages", 2006, MCGRAW-HILL SCIENCE/ENGINEERING/MATH
VAISVILA ET AL., MOL CELL, vol. 84, no. 5, 7 March 2024 (2024-03-07), pages 854 - 866
VAISVILA ET AL., MOL CELL., vol. 84, no. 5, 7 March 2024 (2024-03-07), pages 854 - 866
VAISVILA R ET AL.: "EM-seq: Detection of DNA methylation at single base resolution from picograms of DNA.", BIORXIV, 2019
WEI XIE ET AL: "Base-Resolution Analyses of Sequence and Parent-of-Origin Dependent DNA Methylation in the Mouse Genome", CELL, ELSEVIER, AMSTERDAM NL, vol. 148, no. 4, 29 December 2011 (2011-12-29), pages 816 - 831, XP028458995, ISSN: 0092-8674, [retrieved on 20120127], DOI: 10.1016/J.CELL.2011.12.035 *
WEIRATHER JL ET AL., F1000RESEARCH, vol. 6, 2017, pages 100
WEIRATHER JL ET AL.: "Comprehensive comparison of Pacific Biosciences and Oxford Nanopore Technologies and their applications to transcriptome analysis", F1000RESEARCH, vol. 6, 2017, pages 100
XIAOQI ZHENG ET AL: "MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes", GENOME BIOLOGY, BIOMED CENTRAL LTD, vol. 15, no. 7, 7 August 2014 (2014-08-07), pages 419, XP021192745, ISSN: 1465-6906, DOI: 10.1186/S13059-014-0419-X *
YAMASHITA ET AL., NUCLEIC ACIDS RES., vol. 34, 2006, pages D86 - D89
YANG ET AL., BIO-PROTOCOL, vol. 12, no. 17, 2023, pages 4496
YU ET AL., CELL, vol. 149, 2012, pages 1368 - 80

Similar Documents

Publication Publication Date Title
US20260022424A1 (en) Nucleic acid methylation profiling method
US20260125748A1 (en) Methylation sequencing through methylation preserving amplification with error correction
US20240191290A1 (en) Methods for detection and reduction of sample preparation-induced methylation artifacts
US20250084464A1 (en) Compositions and methods for synthesis and use of probes targeting nucleic acid rearrangements
US20260071265A1 (en) Integrated targeted and whole genome somatic and dna methylation sequencing workflows
EP4486911A1 (fr) Procédés d&#39;analyse de méthylation de cytosine et d&#39;hydroxyméthylation
WO2025090956A1 (fr) Procédés de détection de variants d&#39;acide nucléique à l&#39;aide de sondes de capture
WO2023122740A1 (fr) Compositions et procédés de détection de métastase
WO2025029475A1 (fr) Procédés d&#39;enrichissement de variants nucléotidiques par sélection négative
EP4705514A1 (fr) Procédé de contrôle qualité pour les procédures de conversion enzymatique
US20260009024A1 (en) Non-invasive monitoring of genomic alterations induced by gene-editing therapies
WO2026015794A1 (fr) Procédés de modification de l&#39;adn à l&#39;aide de la désamination spécifique des cpg et de l&#39;excision de la base uracile
WO2026060266A1 (fr) Utilisation de variants du nombre de copies pour l&#39;identification de cellules tumorales faux positives
WO2026102110A1 (fr) Sélection personnalisée du type de dosage de détection d&#39;une maladie minimale résiduelle afin d&#39;optimiser la sensibilité pour chaque patient, sur la base d&#39;un profilage exhaustif des variants tumoraux
WO2026080838A2 (fr) Procédé de détection de variants d&#39;acide nucléique
WO2025207926A1 (fr) Procédés de désamination sélective utilisant des désaminases sensibles au méthyle
WO2026064529A2 (fr) Procédés de détection de variants d&#39;acide nucléique à l&#39;aide d&#39;amorces et de substrats de ligature
WO2025090954A1 (fr) Procédé de détection de variants d&#39;acide nucléique
WO2026102107A1 (fr) Méthodes de détection de variants somatiques
WO2025160433A1 (fr) Procédés d&#39;analyse de lectures de séquençage
WO2026015607A1 (fr) Procédés de partitionnement d&#39;adn hyperméthylé, hypométhylé et non méthylé
WO2025038399A1 (fr) Procédés d&#39;enrichissement méthylé pour séquençage génétique et épigénétique à molécule unique
WO2025235889A1 (fr) Procédés impliquant une pcr groupée multiplexée
WO2025155895A1 (fr) Procédé de profilage de modification d&#39;acide nucléique
WO2025137620A1 (fr) Procédés de séquençage de méthylation de haute qualité et de haute précision